Stay updated on Sitravatinib+Nivolumab in Clear Cell Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib+Nivolumab in Clear Cell Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Sitravatinib+Nivolumab in Clear Cell Renal Cell Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag in the page footer updated from v3.2.0 to v3.3.2, indicating a platform revision. No changes observed in study details, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe government funding/operating status notice has been removed. This does not change the study details, eligibility criteria, or other essential information presented on the page.SummaryDifference0.4%

- Check34 days agoChange DetectedNo significant content changes detected; the page layout and core sections appear the same, with only minor cosmetic spacing and styling tweaks. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check63 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check70 days agoChange DetectedCore terminology updated from 'Clear cell renal carcinoma' to 'Clear cell carcinoma of kidney' and the document/page version updated to v3.1.0.SummaryDifference0.3%

- Check85 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2, signaling a minor update to the page content. The 'Back to Top' element was removed as a non-substantive UI change.SummaryDifference0.2%

Stay in the know with updates to Sitravatinib+Nivolumab in Clear Cell Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib+Nivolumab in Clear Cell Renal Cell Carcinoma Clinical Trial page.